Nuvation Bio (NUVB) AI Stock Analysis

• Market Cap: $796.39M
• Dividend Yield: N/A
• Average Volume (3M): 4.58M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.15
• Revenue Growth: 900.35%
• EPS Growth: 70.25%
• Country: US
• Employees: 273
• Sector: Healthcare
• Sector Strength: 43
• Industry: Biotechnology
• EPS (TTM): -0.17
• Shares Outstanding: 342,272,740
• 10 Day Avg. Volume: 3,728,902
• 30 Day Avg. Volume: 4,577,627
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.33
• Enterprise Value/Revenue: 18.12
• Enterprise Value/Gross Profit: 65.78
• Enterprise Value/Ebitda: -1.25
• 1Y Price Target: $7.80
• Price Target Upside: 198.85% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 45 Neutral
• Price Target: ―

Nuvation Bio's stock is primarily challenged by weak financial performance, characterized by ongoing losses and negative cash flows, despite a strong equity foundation. While there is short-term momentum in the stock price, the lack of sustainable income and negative valuation metrics, such as a negative P/E ratio, weigh heavily on the overall score. The stock's speculative nature and reliance on future growth prospects contribute to its moderate overall score.

Positive Factors

Financial Performance

IBTROZI generated $1.2M in product sales within 13 business days after receiving FDA approval.

Regulatory Approval

Nuvation Bio received full FDA approval for its drug Ibtrozi in line agnostic ROS1+ NSCLC.

Strategic Positioning

Nuvation Bio has a 9-18+ month head start over its competitor Nuvalent in the ROS1+ lung cancer space.

Negative Factors

Clinical Risks

Risks include negative clinical proof-of-concept data for any of the company's drug-drug conjugate (DDC) candidates or any of the other pipeline programs.

Market Risks

Risks include poorer-than-anticipated commercial uptake of company products, particularly taletrectinib, due to higher-than-anticipated levels of competition or other market-related factors.

Short Interest

Short interest is 15.5% of the float.

Nuvation Bio Business Overview & Revenue Model

Company Description

Nuvation Bio (NUVB) is a biotechnology company focused on developing innovative therapies for the treatment of cancer. The company operates within the pharmaceutical and biotechnology sectors and is dedicated to advancing a proprietary pipeline of novel oncology drug candidates. Nuvation Bio aims to address unmet medical needs by targeting multiple tumor types with its differentiated therapeutic approaches.

How the Company Makes Money

Nuvation Bio makes money primarily through the development and commercialization of its pharmaceutical products. The company generates revenue from various streams, including partnerships with other biotech and pharmaceutical companies, licensing agreements, and potential future sales of its drug candidates once they receive regulatory approval. Significant partnerships with industry players or research institutions can also provide funding and collaborative opportunities, contributing to the company's financial growth. Additionally, Nuvation Bio may engage in strategic collaborations to enhance its research and development capabilities, which can also lead to milestone payments and royalties that serve as key revenue streams.

Nuvation Bio Financial Statement Overview

Summary

Nuvation Bio faces significant financial challenges, marked by consistent net losses and negative cash flows, despite a strong equity base and low leverage. The recent revenue increase is a positive sign, yet operational and cash flow improvements are necessary for long-term sustainability. The company's financial health is currently weak, primarily due to its inability to generate positive net income and operating cash flow.

Income Statement

Nuvation Bio has struggled with profitability, exhibiting a negative net profit margin due to substantial net losses over the years. Although there was a notable revenue increase in 2024, margins remain negative, highlighting ongoing operational challenges. The absence of revenue in prior years underscores the lack of stable income streams.

Balance Sheet

The company maintains a strong equity position with a debt-to-equity ratio that indicates low leverage, which is a positive aspect. However, the persistent negative net income has affected the return on equity, which is currently unfavorable. The equity ratio is high, showing that the company is mainly financed through equity, which can be advantageous in managing financial risk.

Cash Flow

Nuvation Bio's cash flow statement reveals a lack of positive operating cash flow, with free cash flow also being negative. This signifies potential issues in cash generation from operations. The company has been relying on financing activities to support cash needs, which may not be sustainable in the long term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	14.36M	7.87M	0.00	0.00	0.00	0.00
Gross Profit	3.95M	795.00K	-222.00K	-484.00K	-368.00K	-103.00K
EBITDA	-207.82M	-566.91M	-99.60M	-119.53M	-89.35M	-43.45M
Net Income	-202.90M	-567.94M	-75.80M	-104.20M	-86.85M	-41.66M
Balance Sheet
Total Assets	647.23M	540.63M	621.48M	672.14M	776.15M	221.79M
Cash, Cash Equivalents and Short-Term Investments	607.72M	502.69M	611.21M	661.01M	765.39M	215.75M
Total Debt	203.37M	8.91M	4.01M	4.26M	3.06M	0.00
Total Liabilities	274.32M	76.84M	16.36M	17.07M	30.15M	6.71M
Stockholders Equity	372.91M	463.79M	605.12M	655.08M	746.00M	215.08M
Cash Flow
Free Cash Flow	-120.22M	-130.57M	-68.07M	-96.48M	-68.47M	-36.67M
Operating Cash Flow	-120.01M	-130.41M	-68.00M	-96.11M	-68.19M	-36.53M
Investing Cash Flow	189.95M	122.70M	8.92M	63.46M	-454.67M	-70.32M
Financing Cash Flow	191.53M	331.00K	628.00K	1.33M	625.53M	133.13M

Nuvation Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.61
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUVB, the sentiment is Positive. The current price of 2.61 is above the 20-day moving average (MA) of 2.41, above the 50-day MA of 2.23, and above the 200-day MA of 2.31, indicating a bullish trend. The MACD of 0.08 indicates Negative momentum. The RSI at 68.25 is Neutral, neither overbought nor oversold. The STOCH value of 72.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUVB.

Nuvation Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ABUS	51 Neutral	$651.78M	―	-52.82%	―	53.23%	35.32%
Sector *	51 Neutral	$7.44B	-0.20	-46.33%	2.27%	23.01%	-2.29%
PRAX	49 Neutral	$1.02B	―	-60.98%	―	338.45%	-19.64%
BCAX	48 Neutral	$570.99M	―	-32.71%	―	―	―
NUVB	45 Neutral	$796.39M	―	-64.40%	―	900.35%	70.25%
XNCR	43 Neutral	$552.75M	―	-29.22%	―	-2.07%	22.52%
RCKT	40 Underperform	$326.95M	―	-69.65%	―	―	10.36%

Nuvation Bio Corporate Events

Nuvation Bio CEO Departs After Achieving Key Goals

On February 12, 2025, Dr. Jerry Wang, CEO of AnHeart Therapeutics, a subsidiary of Nuvation Bio Inc., departed the company after achieving key goals, including regulatory approvals for taletrectinib in China and the U.S., and the integration of AnHeart Therapeutics post-merger. Dr. Wang’s departure was not due to any disagreements, and his role as CEO was deemed unnecessary following these accomplishments.